Table 3 Comparison of HER2 fluorescence in situ hybridization results according to the original HERA classification (FDA-approved guidelines), the ASCO/CAP guidelines of 2007 and the ASCO/CAP guidelines of 2013

From: Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data

 

FDA

ASCO/CAP 2007

ASCO/CAP 2013

FISH positive

cases

FISH equivocal

cases

FISH negative

cases

3359 (55.8%)

NA

2659 (44.2%)

3339 (55.5%)

44 (0.7%)

2635 (43,8)

3380 (56.2%)

113 (1.9%)

2525 (41.9%)

  1. Abbreviation: FISH, fluorescence in situ hybridization.
  2. The numbers represent the amount of patients that have been tested positive, equivocal or negative.
Back to article page